Kymera Therapeutics, Inc. (KYMR) shareholders
Close on Nov 17, 2026Market cap $10.37BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Abigail P. Johnson Joint filing with FMR LLC (14.30%) | 11,681,450 | 14.30% | 13G (passive) amendment | Mar 31, 2026 |
| T. Rowe Price Associates, Inc. | 8,873,588 | 10.70% | 13G (passive) amendment | Aug 31, 2026 |
| Julian C. Baker Joint filing with Baker Bros. Advisors LP (10.90%), Baker Bros. Advisors (GP) LLC (10.90%) and 1 more | 8,676,797 | 10.90% | 13D (active) amendment | Dec 9, 2025 |
| Behzad Aghazadeh Joint filing with Avoro Capital Advisors LLC (9.99%) | 7,750,000 | 9.99% | 13G (passive) amendment | Sep 30, 2024 |
| Wellington Management Company LLP Joint filing with Wellington Management Group LLP (9.20%), Wellington Group Holdings LLP (9.20%) and 1 more | 5,996,873 | 9.00% | 13G (passive) amendment | Mar 31, 2025 |
| FMR LLC Joint filing with Abigail P. Johnson (8.20%) | 5,879,611 | 8.20% | 13G (passive) amendment | Sep 30, 2025 |
| T. Rowe Price Investment Management, Inc. | 5,460,257 | 6.70% | 13G (passive) | Mar 31, 2026 |
| BlackRock, Inc. | 5,450,286 | 6.60% | 13G (passive) amendment | Sep 30, 2026 |
| Wellington Group Holdings LLP Joint filing with Wellington Management Group LLP (7.70%), Wellington Investment Advisors Holdings LLP (7.70%) and 1 more | 5,372,061 | 7.70% | 13G (passive) amendment | Jun 30, 2025 |
| Lampert Mark N Joint filing with Bvf Partners L P/Il (6.30%), Bvf Inc/Il (6.30%) and 1 more | 5,237,151 | 6.30% | 13D (active) amendment | Jun 26, 2026 |
| Wellington Investment Advisors Holdings LLP Joint filing with Wellington Management Group LLP (5.50%), Wellington Group Holdings LLP (5.50%) and 1 more | 4,412,933 | 5.50% | 13G (passive) amendment | Dec 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of KYMR | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 12,349,256 | 14.47% | $1.42B | +649,306 | 0.06% |
| Baker Bros. Advisors LP | 8,657,242 | 10.14% | $992.73M | – | 4.97% |
| Avoro Capital Advisors LLC | 7,474,747 | 8.76% | $857.13M | – | 7.70% |
| Price T Rowe Associates Inc /Md/ | 7,112,980 | 8.33% | $815.65M | +1,052,133 | 0.08% |
| T. Rowe Price Investment Management, Inc. | 6,257,261 | 7.33% | $717.52M | +792,264 | 0.47% |
| BlackRock, Inc. | 5,538,210 | 6.49% | $635.07M | +477,334 | 0.01% |
| Bvf Inc/Il | 3,872,052 | 4.54% | $444.01M | −1,630,658 | 11.35% |
| Wellington Management Group Llp | 3,675,028 | 4.30% | $421.42M | −214,659 | 0.07% |
| Vanguard Portfolio Management LLC | 2,992,193 | 3.50% | $343.11M | +118,137 | 0.02% |
| Siren, L.L.C. | 2,935,830 | 3.44% | $336.65M | −251,000 | 6.81% |
| Vanguard Capital Management LLC | 2,932,378 | 3.43% | $336.26M | +52,054 | 0.01% |
| Atlas Venture Life Science Advisors, LLC | 2,847,541 | 3.34% | $326.53M | −1,730,467 | 37.05% |
| State Street Corp | 2,737,226 | 3.21% | $313.88M | +347,459 | 0.01% |
| Geode Capital Management, LLC | 1,816,331 | 2.13% | $208.32M | +170,981 | 0.01% |
| Capital Research Global Investors | 1,388,881 | 1.63% | $159.26M | −284,394 | 0.02% |
| Goldman Sachs Group Inc | 1,187,333 | 1.39% | $136.15M | +298,924 | 0.01% |
| UBS Group AG | 1,007,777 | 1.18% | $115.56M | −16,075 | 0.01% |
| Alliancebernstein L.P. | 981,521 | 1.15% | $81.75M | +93,486 | 0.03% |
| Driehaus Capital Management LLC | 919,233 | 1.08% | $105.41M | −124,350 | 0.61% |
| Merck & Co., Inc. | 772,165 | 0.90% | $88.54M | – | 16.82% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 275 | 97M | 100.0% | 48 / 97 | 83 / 26 | 8M | 7M |
| Q1 2026 | 256 | 96M | 100.0% | 43 / 96 | 73 / 38 | 16M | 4M |
| Q4 2025 | 255 | 90M | 100.0% | 68 / 99 | 63 / 15 | 14M | 5M |
| Q3 2025 | 210 | 81M | 94.9% | 40 / 81 | 54 / 38 | 8M | 6M |
| Q2 2025 | 210 | 79M | 92.5% | 64 / 69 | 52 / 26 | 10M | 4M |
| Q1 2025 | 173 | 73M | 85.4% | 23 / 64 | 57 / 29 | 6M | 4M |
| Q4 2024 | 180 | 72M | 84.0% | 33 / 60 | 60 / 28 | 7M | 4M |
| Q3 2024 | 176 | 69M | 81.0% | 37 / 54 | 65 / 16 | 13M | 7M |
| Q2 2024 | 157 | 68M | 79.1% | 25 / 58 | 50 / 30 | 4M | 5M |
| Q1 2024 | 164 | 69M | 80.6% | 42 / 59 | 44 / 13 | 13M | 5M |
| Q4 2023 | 136 | 61M | 71.9% | 33 / 37 | 52 / 18 | 7M | 3M |
| Q3 2023 | 121 | 57M | 67.2% | 12 / 49 | 36 / 20 | 2M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
357 funds held KYMR in Q2 2026, 28% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of KYMR | Value | % of fund | As of |
|---|---|---|---|---|---|
| T. Rowe Price New Horizons Fund, Inc. | 2,257,207 | 2.64% | $258.83M | 1.76% | Jun 30, 2026 |
| Fidelity Growth Company Fund | 2,185,407 | 2.56% | $177.94M | 0.18% | May 31, 2026 |
| Vanguard Total Stock Market Index Fund | 2,089,249 | 2.45% | $239.57M | 0.01% | Jun 30, 2026 |
| T. Rowe Price Capital Appreciation Fund | 2,046,104 | 2.40% | $234.63M | 0.33% | Jun 30, 2026 |
| Vanguard Health Care Fund | 1,796,469 | 2.10% | $185.75M | 0.49% | Jul 31, 2026 |
| iShares Russell 2000 ETF | 1,607,649 | 1.88% | $184.35M | 0.22% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 1,509,757 | 1.77% | $173.12M | 0.09% | Jun 30, 2026 |
| SMALLCAP World Fund Inc | 1,352,248 | 1.58% | $155.06M | 0.16% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,272,754 | 1.49% | $145.95M | 1.36% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 924,967 | 1.08% | $106.07M | 0.89% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 868,915 | 1.02% | $99.64M | 0.21% | Jun 30, 2026 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 790,093 | 0.93% | $90.60M | 0.97% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 726,545 | 0.85% | $83.31M | 0.09% | Jun 30, 2026 |
| Vanguard Explorer Fund | 693,227 | 0.81% | $71.68M | 0.32% | Jul 31, 2026 |
| Fidelity Small Cap Index Fund | 684,750 | 0.80% | $70.80M | 0.21% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Nello Mainolfi | Chief Executive Officer, Director | 666,568 | 0.78% | Oct 1, 2026 |
| Brian Adams | Chief Legal Officer | 50,254 | 0.06% | Sep 4, 2026 |
| Terence Rooney | Chief Medical Officer | 38,000 | 0.04% | Jul 27, 2026 |
| Noah Goodman | Chief Business Officer | 47,179 | 0.06% | Jul 2, 2026 |
| Bruce N. Jacobs | Chief Financial Officer | 248,083 | 0.29% | Jul 2, 2026 |
| Jeremy G. Chadwick | Chief Operating Officer | 44,618 | 0.05% | May 27, 2026 |
| Jared Gollob | Chief Medical Officer | 117,134 | 0.14% | Mar 4, 2026 |
| Ellen Chiniara | Chief Legal Officer | 82,326 | 0.10% | Mar 3, 2025 |
| Bruce Booth | Director | 2,396,426 | 2.81% | Jul 2, 2026 |
| Ii Gp Llc Bvf | Director | 2,104,075 | 2.46% | Jun 26, 2026 |
| Value Fund L. P. Biotechnology | Director | 2,104,075 | 2.46% | Jun 26, 2026 |
| Gp Holdings Llc Bvf | Director | – | – | Jun 26, 2026 |
| Inc/Il Bvf | Director | 2,195,696 | 2.57% | Jun 26, 2026 |
| I. Gp Llc Bvf | Director | 294,632 | 0.35% | Jun 26, 2026 |
| Value Fund Ii Lp Biotechnology | Director | 1,671,048 | 1.96% | Jun 26, 2026 |
| Mark N. Lampert | Director | 2,494,688 | 2.92% | Jun 26, 2026 |
| Value Trading Fund OS LP Biotechnology | Director | 2,350,503 | 2.75% | Jun 26, 2026 |
| Partners L. P/Il Bvf | Director | 1,627,928 | 1.91% | Jun 26, 2026 |
| Partners OS Ltd. BVF | Director | – | – | Jun 26, 2026 |
| Jeffrey W. Albers | Director | 5,000 | 0.01% | Jun 25, 2026 |
| Victor Sandor | Director | – | – | Jun 25, 2026 |
| John Maraganore | Director | – | – | Jun 25, 2026 |
| 667, L.P. | Director, 10% owner | 5,516,986 | 6.46% | Jun 25, 2026 |
| Elena Ridloff | Director | 0 | – | Jun 25, 2026 |
| Bros. Advisors (GP) LLC Baker | Director, 10% owner | 6,117,295 | 7.17% | Jun 25, 2026 |
| Brothers Life Sciences LP Baker | Director, 10% owner | – | – | Jun 25, 2026 |
| Felix Baker | Director, 10% owner | 7,955,916 | 9.32% | Jun 25, 2026 |
| Pamela Esposito | Director | 1,000 | 0.00% | Jun 25, 2026 |
| Julian Baker | Director, 10% owner | – | – | Jun 25, 2026 |
| Gorjan Hrustanovic | Director | – | – | Jun 25, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Nello Mainolfi Chief Executive Officer, Director | Oct 1, 2026 | Sale(10b5-1 plan) | −262 | $116.12 | $30.42K | 666,568 |
| Nello Mainolfi Chief Executive Officer, Director | Oct 1, 2026 | Sale(10b5-1 plan) | −8,230 | $115.40 | $949.74K | 666,830 |
| Nello Mainolfi Chief Executive Officer, Director | Oct 1, 2026 | Sale(10b5-1 plan) | −7,601 | $114.43 | $869.78K | 675,060 |
| Nello Mainolfi Chief Executive Officer, Director | Oct 1, 2026 | Sale(10b5-1 plan) | −4,876 | $113.24 | $552.16K | 682,661 |
| Nello Mainolfi Chief Executive Officer, Director | Oct 1, 2026 | Sale(10b5-1 plan) | −5,506 | $112.42 | $618.98K | 687,537 |
| Nello Mainolfi Chief Executive Officer, Director | Oct 1, 2026 | Sale(10b5-1 plan) | −3,525 | $111.44 | $392.83K | 693,043 |
| Nello Mainolfi Chief Executive Officer, Director | Oct 1, 2026 | Option exercise | +30,000 | $2.08 | $62.40K | 696,568 |
| Brian Adams Chief Legal Officer | Sep 4, 2026 | Sale | −2,137 | $117.57 | $251.25K | 50,254 |
| Brian Adams Chief Legal Officer | Sep 4, 2026 | Sale | −3,025 | $116.81 | $353.35K | 52,391 |
| Brian Adams Chief Legal Officer | Sep 4, 2026 | Sale | −1,209 | $115.55 | $139.70K | 55,416 |
| Terence Rooney Chief Medical Officer | Jul 27, 2026 | Award | +38,000 | – | – | 38,000 |
| Nello Mainolfi Chief Executive Officer, Director | Jul 7, 2026 | Sale(10b5-1 plan) | −50,000 | $119.00 | $5.95M | 666,568 |
| Nello Mainolfi Chief Executive Officer, Director | Jul 7, 2026 | Option exercise | +50,000 | $2.08 | $104.00K | 716,568 |
| Nello Mainolfi Chief Executive Officer, Director | Jul 1, 2026 | Sale(10b5-1 plan) | −3,336 | $116.56 | $388.84K | 666,568 |
| Nello Mainolfi Chief Executive Officer, Director | Jul 1, 2026 | Sale(10b5-1 plan) | −24,105 | $114.96 | $2.77M | 713,954 |
| Nello Mainolfi Chief Executive Officer, Director | Jul 1, 2026 | Sale(10b5-1 plan) | −44,050 | $115.69 | $5.10M | 669,904 |
| Nello Mainolfi Chief Executive Officer, Director | Jul 1, 2026 | Sale(10b5-1 plan) | −6,626 | $113.98 | $755.23K | 738,059 |
| Nello Mainolfi Chief Executive Officer, Director | Jul 1, 2026 | Sale(10b5-1 plan) | −1,883 | $112.80 | $212.40K | 744,685 |
| Nello Mainolfi Chief Executive Officer, Director | Jul 1, 2026 | Option exercise | +80,000 | $2.08 | $166.40K | 746,568 |
| Noah Goodman Chief Business Officer | Jul 1, 2026 | Sale(10b5-1 plan) | −3,389 | $114.29 | $387.33K | 47,179 |
| Bruce N. Jacobs Chief Financial Officer | Jun 30, 2026 | Sale(10b5-1 plan) | −6,153 | $116.99 | $719.84K | 248,083 |
| Bruce N. Jacobs Chief Financial Officer | Jun 30, 2026 | Sale(10b5-1 plan) | −3,200 | $117.70 | $376.64K | 244,883 |
| Bruce N. Jacobs Chief Financial Officer | Jun 30, 2026 | Sale(10b5-1 plan) | −7,971 | $115.82 | $923.20K | 254,236 |
| Bruce N. Jacobs Chief Financial Officer | Jun 30, 2026 | Option exercise | +61,378 | $5.33 | $327.14K | 321,992 |
| Bruce N. Jacobs Chief Financial Officer | Jun 30, 2026 | Sale(10b5-1 plan) | −1,500 | $110.54 | $165.81K | 320,492 |
| Bruce N. Jacobs Chief Financial Officer | Jun 30, 2026 | Sale(10b5-1 plan) | −1,700 | $111.57 | $189.67K | 318,792 |
| Bruce N. Jacobs Chief Financial Officer | Jun 30, 2026 | Sale(10b5-1 plan) | −51,375 | $114.77 | $5.90M | 262,207 |
| Bruce N. Jacobs Chief Financial Officer | Jun 30, 2026 | Sale(10b5-1 plan) | −4,110 | $114.19 | $469.32K | 313,582 |
| Bruce N. Jacobs Chief Financial Officer | Jun 30, 2026 | Sale(10b5-1 plan) | −1,100 | $112.79 | $124.07K | 317,692 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −934 | $111.20 | $103.86K | 2,384,685 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −5,549 | $105.78 | $586.97K | 2,446,375 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −14,798 | $106.63 | $1.58M | 2,431,577 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −19,419 | $107.76 | $2.09M | 2,412,158 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −130 | $111.20 | $14.46K | 462,856 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −1,078 | $110.67 | $119.30K | 462,986 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −1,104 | $109.75 | $121.16K | 464,064 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −1,498 | $108.28 | $162.20K | 465,168 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −2,698 | $107.76 | $290.74K | 466,666 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −2,133 | $106.63 | $227.44K | 469,364 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −770 | $105.78 | $81.45K | 471,497 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −7,723 | $110.67 | $854.70K | 2,385,619 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −7,968 | $109.75 | $874.49K | 2,393,342 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −10,848 | $108.28 | $1.17M | 2,401,310 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −3,024 | $107.76 | $325.87K | 466,077 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −2,318 | $106.63 | $247.17K | 469,101 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −848 | $105.78 | $89.70K | 471,419 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −19,093 | $107.76 | $2.06M | 2,412,747 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −14,613 | $106.63 | $1.56M | 2,431,840 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −5,471 | $105.78 | $578.72K | 2,446,453 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −1,239 | $109.75 | $135.98K | 463,150 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −1,688 | $108.28 | $182.78K | 464,389 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −907 | $111.20 | $100.86K | 2,385,747 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −7,602 | $110.67 | $841.31K | 2,386,654 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −1,199 | $110.67 | $132.69K | 461,951 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −157 | $111.20 | $17.46K | 461,794 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −7,833 | $109.75 | $859.67K | 2,394,256 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −10,658 | $108.28 | $1.15M | 2,402,089 |
| Bruce Booth Director | Jun 26, 2026 | Sale(10b5-1 plan) | −1,729 | $118.66 | $205.16K | 472,267 |
| Bruce Booth Director | Jun 26, 2026 | Sale(10b5-1 plan) | −3,069 | $117.85 | $361.68K | 473,996 |
| Bruce Booth Director | Jun 26, 2026 | Sale(10b5-1 plan) | −1,701 | $117.09 | $199.17K | 477,065 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Kymera Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 10,096 shares on Sep 11, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Nello Mainolfi Officer, Director | Oct 1, 2026 | 30,000 | $3.35M | Oct 1, 2026 | Exercise of stock options |
| Brian Adams Officer | Sep 4, 2026 | 6,371 | $747.19K | Sep 4, 2026 | Shares acquired upon vesting of Restricted Stock Units awarded under the Issuer's 2020 Equity Incentive Plan. |
| Jeremy G. Chadwick Officer | Sep 2, 2026 | 10,879 | $1.30M | Sep 2, 2026 | Exercise of Stock Options |
| Nello Mainolfi Officer, Director | Jul 7, 2026 | 50,000 | $5.95M | Jul 7, 2026 | Exercise of stock options |
| Nello Mainolfi Officer, Director | Jul 2, 2026 | 80,000 | $9.14M | Jul 1, 2026 | Exercise of stock options |
| Noah Goodman Officer | Jul 1, 2026 | 3,389 | $388.62K | Jul 1, 2026 | Restricted Stock Units |
| Bruce N. Jacobs Officer | Jun 30, 2026 | 77,109 | $8.43M | Jun 30, 2026 | Exercise of Stock Options |
| Atlas Venture Opportunity Fund I, L.P. Shareholder | Jun 29, 2026 | 10,473 | $1.13M | Jun 29, 2026 | Private Placement |
| Atlas Venture Fund X, L.P. Shareholder | Jun 29, 2026 | 66,177 | $7.16M | Jun 29, 2026 | Private Placement |
| Atlas Venture Opportunity Fund I, L.P. Shareholder | Jun 26, 2026 | 57,451 | $6.69M | Jun 26, 2026 | Private Placement |
| Atlas Venture Fund X, L.P. Shareholder | Jun 26, 2026 | 410,427 | $47.80M | Jun 26, 2026 | Private Placement |
| Partners L. P/Il Bvf Affiliate of Director | Jun 26, 2026 | 1,630,658 | $189.91M | Jun 26, 2026 | Acquired upon the automatic conversion of private shares in connection with the Issuer's initial public offering on August 21, 2020. The private shares were acquired and fully paid for on March 11, 20 |
| Atlas Venture Opportunity Fund I, L.P. Shareholder | Jun 25, 2026 | 67,329 | $6.72M | Jun 25, 2026 | Private Placement |
| Atlas Venture Fund X, L.P. Shareholder | Jun 25, 2026 | 480,992 | $48.04M | Jun 25, 2026 | Private Placement |
| Noah Goodman Officer | Jun 25, 2026 | 5,000 | $499.35K | Jun 25, 2026 | Exercise of Stock Options |
See a number that looks wrong?